Education
About Us
Working with TipRanks
Follow Us
Cullinan Management (CGEM)
NASDAQ:CGEM
CGEM Analyst Ratings
Strong Buy
10 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
CGEM Stock 12 Month Forecast
Average Price Target
$26.71
▲(244.20% Upside)
| Highest Price Target$34.00 | Average Price Target$26.71 | Lowest Price Target$22.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TD Cowen
―
Buy
―
Reiterated
10/20/25
Morgan Stanley
$28
Buy
260.82%
Upside
Reiterated
10/19/25
Promising Clinical Trial Results and Strategic Partnerships Drive Buy Rating for Cullinan ManagementWe model ~$400mn in unadjusted total sales (risk-adjusted ~$250mn), with ~ $200mn unadjusted revenues (~$100mn risk-adjusted) to Cullinan post-profit split. Morgan Stanley & Co. LLC Sean Laaman, Ph.D.
JonesTrading
$34
Buy
338.14%
Upside
Reiterated
10/19/25
Buy Rating for Cullinan Management's Zipalertinib: Promising Efficacy in Challenging EGFR Mutated NSCLC CasesWe think that more patients in the US and EU will get treated with Rybrevant/ EGFR inhibitor in 1L setting. With an overall similar safety profile between firmo and zipalertinib, we believe ArriVent's firmo will get used in the 1L setting due to being a monotherapy regimen (if Ph 3 data in early 2026 is positive), and Cullinan/Taiho’s zipalertinib will get used in 2L setting (now that we see high efficacy in patients with an active brain met). We note that the ESMO discussant, Dr. David Planchard, supported the use of chemo combo in 1L setting to increase efficacy, including CNS response, as was demonstrated in the FLAURA-2 trial with Tagrisso. Tagrisso + chemo demonstrated CNS CR of 48% (19/40) vs 16% (6/38) with Tagrisso monotherapy in 1L classical EGFR mutated NSCLC (Jänne, et al. JCO 2023). Key argument against zipalertinib is being non-brain penetrating.
BTIG
$32
Buy
312.37%
Upside
Reiterated
10/13/25
Promising Efficacy of Zipalertinib in EGFR NSCLC with CNS Involvement Justifies Buy Rating for Cullinan ManagementWe therefore see zipalertinib's ability to decrease CNS lesions in these patients as an additional point of differentiation vs. amivantamab which excluded patients with untreated active brain metastases in its PAPILLON (1L setting) and CHRYSALIS (2L setting) clinical trials. Also of note, Cohort C included patients with ex20ins mutations as well as other uncommon mutations. Taken together with previously reported encouraging preliminary interim results from Cohort D (patients with uncommon non-ex20ins mutations), we think these data further strengthen zipalertinib's compelling use case across a broader TAM consisting of both ex20ins and other uncommon non-ex20ins EGFR NSCLC subsets. Mgmt. will be presenting these results at ESMO 2025 on 10am CEST.
Wedbush
$23
Buy
196.39%
Upside
Reiterated
10/13/25
H.C. Wainwright
$24
Buy
209.28%
Upside
Reiterated
09/12/25
Promising Trial Results and Strategic Plans Justify Buy Rating for Cullinan ManagementValuation and Risks. We assess Cullinan using a discounted cash flow (DCF)-based valuation methodology, with a 70% probability of launch for zipalertinib in exon 20+ NSCLC and a 20% probability of launch for CLN-978 in SLE. In addition, we employ an 11% discount rate, a 29% effective tax rate, and a 1.0% terminal growth rate.
William Blair
―
Buy
―
Reiterated
09/09/25
Promising Drug Pipeline and Strategic Collaborations Drive Buy Rating for Cullinan ManagementWe believe zipalertinib continues to show strong efficacy in previously treated (with both chemotherapy and Rybrevant) patients, which along with its favorable tolerability profile should bode well for potential uptake in the second-line setting (pending NDA submission planned by the end of 2025). Zipalertinib has also demonstrated encouraging initial activity in uncommon EGFR mutated NSCLC, which could support a meaningful expansion opportunity. We highlight in greater detail below the datasets and other relevant data points from Dizal Pharma’s Zegfrovy (sunvozertinib) and ArriVent’s (AVBP $19.87) firmonertinib, which have competitive read-through to zipalertinib.
Leerink Partners
―
Buy
―
Reiterated
09/04/25
Cullinan Management's Strategic Adjustments and Pipeline Development Justify Buy RatingWe spoke to management regarding the guidance change, which appears to be driven by slower enrollment due to certain eligibility criteria. To accelerate enrollment, the company has submitted an amended protocol with two key changes. First, the SLEDAI total score at screening will be lowered from ≥8 to ≥6. Second, the prior treatment criteria will be liberalized to allow for a less heavily pretreated population. Previously, patients needed to have inadequate response to at least two treatments, including at least one immunosuppressive or biologic SoC, and this has been revised to inadequate response to at least one immunosuppressant or biologic used to treat SLE.
UBS
$24
Buy
209.28%
Upside
Reiterated
08/18/25
Clear Street
$22
Buy
183.51%
Upside
Reiterated
08/08/25
Stifel Nicolaus
$22
Buy
183.51%
Upside
Initiated
06/11/25
TR | OpenAI - 4o
―
Sell
―
Downgraded
05/01/25
AI Generated ArticleAI Generated Article
Guggenheim
$30
Buy
286.60%
Upside
Reiterated
02/28/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TD Cowen
―
Buy
―
Reiterated
10/20/25
Morgan Stanley
$28
Buy
260.82%
Upside
Reiterated
10/19/25
Promising Clinical Trial Results and Strategic Partnerships Drive Buy Rating for Cullinan ManagementWe model ~$400mn in unadjusted total sales (risk-adjusted ~$250mn), with ~ $200mn unadjusted revenues (~$100mn risk-adjusted) to Cullinan post-profit split. Morgan Stanley & Co. LLC Sean Laaman, Ph.D.
JonesTrading
$34
Buy
338.14%
Upside
Reiterated
10/19/25
Buy Rating for Cullinan Management's Zipalertinib: Promising Efficacy in Challenging EGFR Mutated NSCLC CasesWe think that more patients in the US and EU will get treated with Rybrevant/ EGFR inhibitor in 1L setting. With an overall similar safety profile between firmo and zipalertinib, we believe ArriVent's firmo will get used in the 1L setting due to being a monotherapy regimen (if Ph 3 data in early 2026 is positive), and Cullinan/Taiho’s zipalertinib will get used in 2L setting (now that we see high efficacy in patients with an active brain met). We note that the ESMO discussant, Dr. David Planchard, supported the use of chemo combo in 1L setting to increase efficacy, including CNS response, as was demonstrated in the FLAURA-2 trial with Tagrisso. Tagrisso + chemo demonstrated CNS CR of 48% (19/40) vs 16% (6/38) with Tagrisso monotherapy in 1L classical EGFR mutated NSCLC (Jänne, et al. JCO 2023). Key argument against zipalertinib is being non-brain penetrating.
BTIG
$32
Buy
312.37%
Upside
Reiterated
10/13/25
Promising Efficacy of Zipalertinib in EGFR NSCLC with CNS Involvement Justifies Buy Rating for Cullinan ManagementWe therefore see zipalertinib's ability to decrease CNS lesions in these patients as an additional point of differentiation vs. amivantamab which excluded patients with untreated active brain metastases in its PAPILLON (1L setting) and CHRYSALIS (2L setting) clinical trials. Also of note, Cohort C included patients with ex20ins mutations as well as other uncommon mutations. Taken together with previously reported encouraging preliminary interim results from Cohort D (patients with uncommon non-ex20ins mutations), we think these data further strengthen zipalertinib's compelling use case across a broader TAM consisting of both ex20ins and other uncommon non-ex20ins EGFR NSCLC subsets. Mgmt. will be presenting these results at ESMO 2025 on 10am CEST.
Wedbush
$23
Buy
196.39%
Upside
Reiterated
10/13/25
H.C. Wainwright
$24
Buy
209.28%
Upside
Reiterated
09/12/25
Promising Trial Results and Strategic Plans Justify Buy Rating for Cullinan ManagementValuation and Risks. We assess Cullinan using a discounted cash flow (DCF)-based valuation methodology, with a 70% probability of launch for zipalertinib in exon 20+ NSCLC and a 20% probability of launch for CLN-978 in SLE. In addition, we employ an 11% discount rate, a 29% effective tax rate, and a 1.0% terminal growth rate.
William Blair
―
Buy
―
Reiterated
09/09/25
Promising Drug Pipeline and Strategic Collaborations Drive Buy Rating for Cullinan ManagementWe believe zipalertinib continues to show strong efficacy in previously treated (with both chemotherapy and Rybrevant) patients, which along with its favorable tolerability profile should bode well for potential uptake in the second-line setting (pending NDA submission planned by the end of 2025). Zipalertinib has also demonstrated encouraging initial activity in uncommon EGFR mutated NSCLC, which could support a meaningful expansion opportunity. We highlight in greater detail below the datasets and other relevant data points from Dizal Pharma’s Zegfrovy (sunvozertinib) and ArriVent’s (AVBP $19.87) firmonertinib, which have competitive read-through to zipalertinib.
Leerink Partners
―
Buy
―
Reiterated
09/04/25
Cullinan Management's Strategic Adjustments and Pipeline Development Justify Buy RatingWe spoke to management regarding the guidance change, which appears to be driven by slower enrollment due to certain eligibility criteria. To accelerate enrollment, the company has submitted an amended protocol with two key changes. First, the SLEDAI total score at screening will be lowered from ≥8 to ≥6. Second, the prior treatment criteria will be liberalized to allow for a less heavily pretreated population. Previously, patients needed to have inadequate response to at least two treatments, including at least one immunosuppressive or biologic SoC, and this has been revised to inadequate response to at least one immunosuppressant or biologic used to treat SLE.
UBS
$24
Buy
209.28%
Upside
Reiterated
08/18/25
Clear Street
$22
Buy
183.51%
Upside
Reiterated
08/08/25
Stifel Nicolaus
$22
Buy
183.51%
Upside
Initiated
06/11/25
TR | OpenAI - 4o
―
Sell
―
Downgraded
05/01/25
AI Generated ArticleAI Generated Article
Guggenheim
$30
Buy
286.60%
Upside
Reiterated
02/28/25
Best Analysts Covering Cullinan Management
1 Month
xxx
Success Rate
5/12 ratings generated profit
Average Return
+4.38%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 41.67% of your transactions generating a profit, with an average return of +4.38% per trade.
3 Months
xxx
Success Rate
6/12 ratings generated profit
Average Return
+9.58%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +9.58% per trade.
1 Year
Success Rate
7/12 ratings generated profit
Average Return
+23.63%
reiterated a buy rating 3 months ago
Copying Kaveri Pohlman's trades and holding each position for 1 Year would result in 58.33% of your transactions generating a profit, with an average return of +23.63% per trade.
2 Years
xxx
Success Rate
5/10 ratings generated profit
Average Return
-16.97%
reiterated a xxx
rating 13 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 50.00% of your transactions generating a profit, with an average return of -16.97% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
CGEM Analyst Recommendation Trends
Rating
Jun 25
Jul 25
Aug 25
Sep 25
Oct 25
Strong Buy
13
12
14
13
15
Buy
11
9
9
8
7
Hold
1
0
0
0
0
Sell
1
1
0
0
0
Strong Sell
0
0
0
0
0
total
26
22
23
21
22
Each month's total comprises the sum of three months' worth of ratings.
CGEM Financial Forecast
CGEM Stock Forecast FAQ
What is CGEM’s average 12-month price target, according to analysts?
Based on analyst ratings, Cullinan Management’s 12-month average price target is 26.71.
What is CGEM’s upside potential, based on the analysts’ average price target?
Cullinan Management has 244.20% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is CGEM a Buy, Sell or Hold?
Cullinan Management has a consensus rating of Strong Buy which is based on 10 buy ratings, 0 hold ratings and 0 sell ratings.
What is Cullinan Management’s price target?
The average price target for Cullinan Management is 26.71. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $34.00 ,the lowest forecast is $22.00. The average price target represents 244.20% Increase from the current price of $7.76.
The highest analyst price target is $34.00 ,the lowest forecast is $22.00. The average price target represents 244.20% Increase from the current price of $7.76.
What do analysts say about Cullinan Management?
Cullinan Management’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.
How can I buy shares of CGEM?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.